Get App
PRE MARKET
Gift Nifty indicate a negative start for the broader index in India, with a loss of 71.5 points or 0.29 percent. The Nifty futures were trading around 24,358.50 level.
Wall Street stocks advanced on Tuesday while crude and gold prices slid as investors juggled corporate earnings, signs of progress in U.S. President Donald Trump’s tariff negotiations, and increased odds of a global recession.
All three major U.S. stock indexes were modestly higher, with the blue-chip Dow out front.
The Dow Jones Industrial Average rose 300.03 points, or 0.75%, to 40,527.62, the S&P 500 rose 32.07 points, or 0.58%, to 5,560.82 and the Nasdaq Composite rose 95.19 points, or 0.55%, to 17,461.32.
The Asian stocks traded mixed.
Japan’s Nikkei was up by 0.09 percent and Singapore’s Straits times was also up by 0.23 percent whereas, Hang Seng and KOSPI were down by over 0.5 percent each.
STOCKS TODAY
Infosys
The digital services and consulting company announced the launch of Infosys Topaz for SAP S/4HANA Cloud, an AI-first suite. This offering will help enterprises harness the power of AI and Gen AI in their SAP S/4HANA Cloud transformation journey.
State Bank of India
The Board will meet on May 3 to consider raising equity during FY26 through follow-on public offer (FPO), rights issue, qualified institutional placement (QIP), or any other mode. The Board will also consider the March quarter and FY25 earnings on the same day.
Prestige Estate Projects
The company has received approval from the Real Estate Regulatory Authority (RERA) and has launched the residential project ‘The Prestige City – Indirapuram’ in the National Capital Region (NCR). The gross development value (GDV) of the project is estimated at over Rs 9,000 crore.
Strides Pharma Science
The company’s subsidiary, Strides Pharma Inc, in the US has acquired four approved ANDAs for the US market from Nostrum Laboratories Inc., USA. The portfolio comprises liquids and immediate-release solid orals in therapeutic segments that treat urinary tract infections (UTIs), pain management, allergy symptoms, attention deficit disorder (ADD/ADHD), and narcolepsy. The cumulative market size for the acquired portfolio is $57 million, as per IQVIA 2025 data.
Alembic Pharmaceticals
The company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Oncology (injectable and oral solid) formulation facility (F-2) at Panelav. The US FDA conducted the inspection on October 7–8, 2024.
Source – Moneycontrol
Disclaimer: Investments in the Securities market and Mutual Funds are subject to market risks. Read all the related documents carefully before investing | The securities are quoted as an example and not as a recommendation | Brokerage will not exceed the SEBI-prescribed limit | Margins will be collected as per the exchange norms.